Cancer immunotherapies, such as antibodies blocking programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) interactions, have demonstrated clinical activity in diverse oncological indications (1). Here, PDCD1 is linked to cancer.